Massimo Di Maio
Overview
Explore the profile of Massimo Di Maio including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
420
Citations
5959
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Calandri M, Brino J, Yevich S, Pujol J, Zarqane H, Bonnet B, et al.
Eur Radiol
. 2025 Mar;
PMID: 40055230
Objectives: To evaluate the reproducibility of the PEARL approach to decrease pneumothorax rates by different board-certified radiologists across multiple medical centers using standard CT units. Materials And Methods: This multicenter...
2.
Maglietta G, Damato A, Finotto S, Mandara M, Tamberi S, Grisanti S, et al.
Eur J Cancer
. 2025 Feb;
219:115296.
PMID: 39970525
Background: The oral factor Xa inhibitor, edoxaban, is effective and safe in cancer-associated Venous Thromboembolism (VTE) treatment. The EDOI study aims to evaluate compliance and quality of life (QoL) in...
3.
Marandino L, Trastu F, Ghisoni E, Lombardi P, Mariniello A, Reale M, et al.
BMJ Oncol
. 2025 Jan;
2(1):e000021.
PMID: 39886519
Objective: To assess time trends in the inclusion of health-related quality of life (QoL) among study endpoints and in the reporting of QoL results in study publications, randomised phase III...
4.
5.
Zagami P, Esposito A, Taurelli Salimbeni B, Berton Giachetti P, Scafetta R, Lambertini M, et al.
Breast
. 2025 Jan;
79:103875.
PMID: 39826385
Purpose: CDK4/6 inhibitors (CDK4/6i) use has revolutionized the treatment of hormone receptor-positive/human epidermal growth factor receptor 2 negative (HR+/HER2-) metastatic breast cancer. The choice of a specific CDK4/6i may be...
6.
Filippini D, Carosi F, Panepinto O, Neri G, Nobili E, Tober N, et al.
Heliyon
. 2024 Dec;
10(23):e40671.
PMID: 39687101
Background: Patients with head and neck cancer (HNC) bear a significant load, due to both disease-related symptoms and to toxicities associated with treatments. Evaluating quality of life (QoL) is crucial...
7.
Saporita I, Calabrese M, Poletto S, Turco F, Di Stefano R, Caffo O, et al.
Clin Genitourin Cancer
. 2024 Nov;
23(1):102255.
PMID: 39615118
Background: 20% of prostate cancer (PC) patients harbor germinal or somatic alterations in homologous recombination repair (HRR) genes, including BRCA1/2. BRCA mutations represent predictive biomarkers for treatment with polyadenosine diphosphate-ribose...
8.
Filippi R, Brandi G, Casadei-Gardini A, Leone F, Silvestris N, Satolli M, et al.
Cancer Invest
. 2024 Nov;
43(1):59-69.
PMID: 39601419
Despite a biologically established causative role of viral hepatitis (VH), i.e. HBV and HCV infections, on intrahepatic cholangiocarcinoma (ICC), only few large Western cohorts exploring the association between VH and...
9.
Iacovino M, Celant S, Tomassini L, Arenare L, Caglio A, Canciello A, et al.
Lancet Reg Health Eur
. 2024 Oct;
44:101012.
PMID: 39444700
[This retracts the article DOI: 10.1016/j.lanepe.2024.100973.].
10.
Valsecchi A, Giovanardi F, Malandrini F, Meregaglia M, Servetto A, Bennati C, et al.
Breast
. 2024 Oct;
78:103817.
PMID: 39362075
Background: Inclusion of patient-reported outcomes (PROs) in oncology clinical trials is strongly recommended. However, selecting the most appropriate patient-reported outcome measures (PROMs) is not easy. This study aimed to develop...